APPLE STUDY

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本试验的目的是评估降脂药物的疗效阿托伐他汀对SLE儿童动脉粥样硬化发展的影响，该动脉粥样硬化使SLE儿童在成年后易发生心血管事件，以评估中期阿托伐他汀治疗的安全性。（36个月）使用阿托伐他汀治疗儿童，通过建立一个前瞻性随访的儿童系统性红斑狼疮患者队列，进一步描述儿童系统性红斑狼疮的病程，并建立一个机制，利用儿童关节炎和风湿病研究联盟（CARRA）（前儿科风湿病研究网络（PRRN））和杜克临床研究所（DCRI）进行罕见儿科风湿病的临床试验。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objectives of this trial are to assess the efficacy of a lipid-lowering agent (atorvastatin) on the development of atherosclerosis that predisposes children with SLE to cardiovascular events in adulthood, to assess the safety of intermediate-term (36 months) treatment of children with atorvastatin, to further characterize the course of SLE in children, by establishing a cohort of pediatric SLE patients to be followed prospectively, and to establish a mechanism for conducting clinical trials in rare pediatric rheumatic diseases using the Children's Arthritis and Rheumatology Research Alliance (CARRA) (formerly Pediatric Rheumatology Research Network (PRRN)) and the Duke Clinical Research Institute (DCRI).